Literature DB >> 32518204

The Lymphatic Cell Environment Promotes Kaposi Sarcoma Development by Prox1-Enhanced Productive Lytic Replication of Kaposi Sarcoma Herpes Virus.

Dongwon Choi1,2, Eunkyung Park1,2, Kyu Eui Kim1,2, Eunson Jung1,2, Young Jin Seong1,2, Luping Zhao1,2, Shrimika Madhavan1,2, George Daghlian1,2, Hansuh H Lee1,2, Patill T Daghlian1,2, Saren Daghlian1,2, Khoa Bui1,2, Chester J Koh3, Alex K Wong1, Il-Taeg Cho1,2, Young-Kwon Hong4,2.   

Abstract

Kaposi sarcoma is the most common cancer in human immunodeficiency virus-positive individuals and is caused by Kaposi sarcoma-associated herpesvirus (KSHV). It is believed that a small number of latently infected Kaposi sarcoma tumor cells undergo spontaneous lytic reactivation to produce viral progeny for infection of new cells. Here, we use matched donor-derived human dermal blood and lymphatic endothelial cells (BEC and LEC, respectively) to show that KSHV-infected BECs progressively lose viral genome as they proliferate. In sharp contrast, KSHV-infected LECs predominantly entered lytic replication, underwent cell lysis, and released new virus. Continuous lytic cell lysis and de novo infection allowed LEC culture to remain infected for a prolonged time. Because of the strong propensity of LECs toward lytic replication, LECs maintained virus as a population, despite the death of individual host cells from lytic lysis. The master regulator of lymphatic development, Prox1, bound the promoter of the RTA gene to upregulate its expression and physically interacted with RTA protein to coregulate lytic genes. Thus, LECs may serve as a proficient viral reservoir that provides viral progeny for continuous de novo infection of tumor origin cells, and potentially BECs and mesenchymal stem cells, which give rise to Kaposi sarcoma tumors. Our study reveals drastically different host cell behaviors between BEC and LEC and defines the underlying mechanisms of the lymphatic cell environment supporting persistent infection in Kaposi sarcoma tumors. SIGNIFICANCE: This study defines the mechanism by which Kaposi's sarcoma could be maintained by virus constantly produced by lymphatic cells in HIV-positive individuals. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32518204      PMCID: PMC7759148          DOI: 10.1158/0008-5472.CAN-19-3105

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  54 in total

1.  Productive lytic replication of a recombinant Kaposi's sarcoma-associated herpesvirus in efficient primary infection of primary human endothelial cells.

Authors:  Shou-Jiang Gao; Jian-Hong Deng; Fu-Chun Zhou
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

2.  Prox1 promotes lineage-specific expression of fibroblast growth factor (FGF) receptor-3 in lymphatic endothelium: a role for FGF signaling in lymphangiogenesis.

Authors:  Jay W Shin; Michael Min; Fréderic Larrieu-Lahargue; Xavier Canron; Rainer Kunstfeld; Lynh Nguyen; Janet E Henderson; Andreas Bikfalvi; Michael Detmar; Young-Kwon Hong
Journal:  Mol Biol Cell       Date:  2005-11-16       Impact factor: 4.138

3.  The structure and coding organization of the genomic termini of Kaposi's sarcoma-associated herpesvirus.

Authors:  M Lagunoff; D Ganem
Journal:  Virology       Date:  1997-09-15       Impact factor: 3.616

Review 4.  Kaposi's sarcoma herpesvirus-induced endothelial cell reprogramming supports viral persistence and contributes to Kaposi's sarcoma tumorigenesis.

Authors:  Silvia Gramolelli; Päivi M Ojala
Journal:  Curr Opin Virol       Date:  2017-10-12       Impact factor: 7.090

5.  Absence of human herpesvirus 8 DNA sequences in neoplastic Kaposi's sarcoma cell lines.

Authors:  L Flamand; R A Zeman; J L Bryant; Y Lunardi-Iskandar; R C Gallo
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1996-10-01

6.  Kaposi's sarcoma-associated herpesvirus K3 and K5 ubiquitin E3 ligases have stage-specific immune evasion roles during lytic replication.

Authors:  Kevin Brulois; Zsolt Toth; Lai-Yee Wong; Pinghui Feng; Shou-Jiang Gao; Armin Ensser; Jae U Jung
Journal:  J Virol       Date:  2014-06-04       Impact factor: 5.103

7.  Angiogenic properties of Kaposi's sarcoma-derived cells after long-term culture in vitro.

Authors:  S Z Salahuddin; S Nakamura; P Biberfeld; M H Kaplan; P D Markham; L Larsson; R C Gallo
Journal:  Science       Date:  1988-10-21       Impact factor: 47.728

8.  Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture.

Authors:  R Renne; W Zhong; B Herndier; M McGrath; N Abbey; D Kedes; D Ganem
Journal:  Nat Med       Date:  1996-03       Impact factor: 53.440

9.  Epigenetic analysis of KSHV latent and lytic genomes.

Authors:  Zsolt Toth; Dennis T Maglinte; Sun Hwa Lee; Hye-Ra Lee; Lai-Yee Wong; Kevin F Brulois; Stacy Lee; Jonathan D Buckley; Peter W Laird; Victor E Marquez; Jae U Jung
Journal:  PLoS Pathog       Date:  2010-07-22       Impact factor: 6.823

Review 10.  Cellular origin of Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus-induced cell reprogramming.

Authors:  Laila Cancian; Amy Hansen; Chris Boshoff
Journal:  Trends Cell Biol       Date:  2013-05-17       Impact factor: 20.808

View more
  2 in total

1.  Molecular Mechanisms of Kaposi Sarcoma Development.

Authors:  Andy Karabajakian; Isabelle Ray-Coquard; Jean-Yves Blay
Journal:  Cancers (Basel)       Date:  2022-04-07       Impact factor: 6.575

2.  Kaposi's Sarcoma-Associated Herpesvirus Reactivation by Targeting of a dCas9-Based Transcription Activator to the ORF50 Promoter.

Authors:  Endrit Elbasani; Francesca Falasco; Silvia Gramolelli; Veijo Nurminen; Thomas Günther; Jere Weltner; Diego Balboa; Adam Grundhoff; Timo Otonkoski; Päivi M Ojala
Journal:  Viruses       Date:  2020-08-27       Impact factor: 5.048

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.